Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 4, 2011, Pages 518-524

  Inoue, Y ^a,b   Saito, T ^a   Ogawa, K ^a   Nishio, Y ^a   Kosugi, S ^a   Suzuki, Y ^a   Shibuya, Y ^a   Kato, M ^a   Takahashi, M ^a   Miura, I ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

allogeneic hematopoietic stem cell transplantation; cyclosporine A; higher peak concentrations; pharmacokinetics

Indexed keywords

CYCLOSPORIN A; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CYCLOSPORINE; DRUG MONITORING; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 79960107918     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01199.x     Document Type: Article

References (24)

1. Ptachcinski RJ, Venkataramanan R, Burkart GJ, (1986) Clinical pharmacokinetics of cyclosporine. Clinical Pharmacokinetics, 11, 107-132.
2. Kahan BD, (1986) Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation, 40, 457-476.
3. Grevel J, Welsh MS, Kahan BD, (1989) Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Therapeutic Drug Monitoring, 11, 246-248. (Pubitemid 19115154)
4. Lindholm A, Kahan BD, (1993) Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clinical Pharmacology and Therapeutics, 54, 205-218. (Pubitemid 23265051)
5. Levy G, Burra P, Cavallari A, et al. (2002) Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-HR post-dose levels (C2). Transplantation, 73, 953-957.
6. Canadian Neoral Renal Transplantation Study Group (2001) Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation, 72, 1024-1032.
7. Mahalati K, Belituky P, West K, et al. (2001) Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. Journal of the American Society of Nephrology, 12, 828-833. (Pubitemid 32246712)
8. Ogawa N, Kanda Y, Matsubara M, et al. (2004) Increased incidence of acute graft-versus-host disease with continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transplantation, 33, 549-552. (Pubitemid 38425787)
9. Oshima K, Kanda Y, Nakasone H, et al. (2007) Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. American Journal of Hematology, 83, 226-232. (Pubitemid 351303948)
10. Grant D, Kneteman N, Tchervenkov J, et al. (1999) Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection result of prospective, randomized, comparison of Neoral and Sandimmune for liver transplantation. Transplantation, 67, 1133-1137. (Pubitemid 29205575)
11. Andersson BS, Kashyap A, Gian V, et al. (2002) Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCY2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II Study. Biology of Blood and Marrow Transplantation, 8, 145-154. (Pubitemid 34285073)
12. Socie G, Crift RA, Blaise D, et al. (2001) Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long term follow-up of 4 randomized studies. Blood, 98, 3569-3574.
13. Yuji K, Miyakoshi S, Kato D, et al. (2005) Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma. Biology of Blood and Marrow Transplantation, 11, 314-318. (Pubitemid 40450759)
14. Giralt S, Thall PF, Khouri I, et al. (2001) Melphalan and prine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood, 97, 631-637. (Pubitemid 32113394)
15. Glucksberg H, Storb R, Ferfer A, et al. (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation, 18, 295-304.
16. Kanda Y, Mineishi S, Saito T, et al. (2001) Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogenic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplantation, 27, 437-444. (Pubitemid 32201353)
17. Alvarez JS, Sacristan JA, Alsar MJ, (1992) Comparison of a monoclonal antibody fluorescent polarization immunoassay with monoclonal antibody radioimmunoassay for cyclosporine determination in whole blood. Therapeutic Drug Monitoring, 14, 78-80.
18. Nash RA, Antin JH, Karanes C, et al. (2000) Phase 3 study comparing merthotrexate and tacrolimus with merthotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood, 96, 2062-2068.
19. Ratanatharathorn V, Nash RA, Przepiorka D, et al. (1998) Phase III study comparing merthotrexate and tacrolimus (Prograf, FK506) with merthotrexate and cyclosporine for acute graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood, 92, 2303-2314. (Pubitemid 28452971)
20. Cantarovich M, Barkun J, Tchervenkov JI, Besner J-G, Aspeslet L, Metrakos P, (1998) Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hour post-dose levels in stable liver transplant patients. Transplantation, 66, 1621-1627. (Pubitemid 29034981)
21. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T, (1993) Human P-glycoprotein transports cyclosporine A and FK506. Journal of Biological Chemistry, 268, 6077-6080. (Pubitemid 23099291)
22. Christians U, Schmitz V, Haschke M, (2005) Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opinion on Drug Metabolism & Toxicology, 1, 641-654.
23. Watkins PB, (1992) Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterology Pharmacology, 21, 511-526.
24. Schultz KR, Nevill TJ, Balshaw RF, et al. (2000) Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporine A in the first month after bone marrow transplantation. Bone Marrow Transplantation, 26, 545-551.